A Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11

Recruiting

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(1 site)

China

The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu